|
| Press Releases |
|
 |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
| Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
| Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
| Thursday, March 21, 2024 |
|
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
| LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas. more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as one of the Nadeshiko Brand 2024, as a listed company excelling in the promotion of women in the workplace. more info >> |
|
| Wednesday, March 6, 2024 |
|
|
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the U.S. more info >> |
|
|
エーザイ、早期アルツハイマー病の診断の簡便化を支援するためC2N Diagnostics LLCに出資 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社米国子会社エーザイ・インクが、C2N Diagnostics LLC（本社：米国ミズーリ州セントルイス 以下 C2N）による米国におけるアルツハイマー病（AD）の血液診断の実用化ならびに、アクセス、アフォーダビリティ、および利用の拡大に向けた取り組みを支援するため、同社に最大15百万米ドルの出資を決定したことをお知らせします。 more info >> |
|
| Thursday, February 29, 2024 |
|
|
エーザイ、第18回アルツハイマー・パーキンソン病学会（AD/PDTM2024）において、レカネマブをはじめとするアルツハイマー病に関する最新研究成果を発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、抗Aβプロトフィブリル＊抗体レカネマブ（一般名、製品名「レケンビ」、米国ブランド名「LEQEMBI」）をはじめとする当社のアルツハイマー病（AD）ポートフォリオに関する最新研究成果について、口頭発表10演題を含む合計18演題を、3月5日から９日までポルトガル・リスボンおよびバーチャルで開催される「第18回アルツハイマー・パーキンソン病学会（International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders：AD/PD™ 2024）において発表することをお知らせします。 more info >> |
|
| Wednesday, February 21, 2024 |
|
|
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050 |
| Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
調味品龍頭來襲！海天味業啟動港股招股
Jun 13, 2025 23:14 HKT/SGT
|
|
|
调味品龙头来袭！海天味业启动港股招股
Jun 13, 2025 23:02 HKT/SGT
|
|
|
SAP商業AI持續釋放數據價值 驅動企業韌性增長
Jun 13, 2025 22:52 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Annual Results
Jun 13, 2025 21:49 HKT/SGT
|
|
|
達豐設備服務有限公司公佈2024/25全年業績
Jun 13, 2025 21:38 HKT/SGT
|
|
|
达丰设备服务有限公司公布2024/25全年业绩
Jun 13, 2025 21:34 HKT/SGT
|
|
|
Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC
Jun 13, 2025 20:38 HKT/SGT
|
|
|
義合控股(1662.HK)附屬APEL與生產力局攜手打造智能微工廠正式投產
Jun 13, 2025 20:20 HKT/SGT
|
|
|
义合控股(1662.HK)附属APEL与生产力局携手打造智能微工厂正式投产
Jun 13, 2025 19:42 HKT/SGT
|
|
|
Jacobson Pharma Announces FY2025 Annual Results
Jun 13, 2025 19:16 HKT/SGT
|
|
|
雅各臣公佈二零二五財年全年業績 持續經營業務溢利飈升43.1％至3.0億港元
Jun 13, 2025 19:06 HKT/SGT
|
|
|
Desert Mirage or Musical Revolution? ESCAPE Records' Secret Vault Opens, Revealing a Hidden Sonic Sanctuary
Jun 13, 2025 19:00 HKT/SGT
|
|
|
雅各臣公布二零二五财年全年业绩 持续经营业务溢利飙升43.1％至3.0亿港元
Jun 13, 2025 18:53 HKT/SGT
|
|
|
第八届贸发局「创业快綫」10间优胜初创诞生
Jun 13, 2025 16:38 HKT/SGT
|
|
|
第八屆貿發局「創業快綫」10間優勝初創誕生
Jun 13, 2025 15:53 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
